Market capitalization | €8.93b |
Enterprise Value | €8.93b |
P/E (TTM) P/E ratio | 13.10 |
EV/FCF (TTM) EV/FCF | 11.83 |
EV/Sales (TTM) EV/Sales | 2.75 |
P/S ratio (TTM) P/S ratio | 2.75 |
P/B ratio (TTM) P/B ratio | 2.21 |
Dividend yield | 1.11% |
Last dividend (FY23) | €1.20 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
16 Analysts have issued a Ipsen forecast:
16 Analysts have issued a Ipsen forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3,250 3,250 |
4%
4%
|
|
Gross Profit | 2,632 2,632 |
2%
2%
|
|
EBITDA | 1,383 1,383 |
7%
7%
|
EBIT (Operating Income) EBIT | 1,008 1,008 |
8%
8%
|
Net Profit | 681 681 |
52%
52%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
Head office | France |
CEO | David Loew |
Employees | 5,325 |
Founded | 1998 |
Website | www.ipsen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.